Delivering Scientific Advances That Impact Patients' Lives

Geno Germano

President / General Manager

Specialty Care & Oncology Business Units

J.P. Morgan Healthcare Conference

January 11, 2011

ADVANCING SCIENCE IMPROVING LIVES

Pfizer

Forward-Looking Statements

- Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer's 2009 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.
- These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section.

Our Operating Model Drives Strong Alignment Between R&D and Business Units



Together, the Research and Business Units Utilize New Tools Designed for Creating New Standards of Care



- Tools & Processes are integrated to demonstrate
  - Why BUs should invest in this program?
  - Why regulators will approve?
  - Why physicians and patients will use?
  - Why payers will pay?
- How to create a new or differentiated standard of care

Innovative Therapies in Key Areas of Unmet Medical Need

Neuroscience

Pain/Inflammation

Infectious Diseases



Oncology



Metabolic Disorders

Our Focus is on High Priority Disease Areas Using Various Modalities

Vaccines

Small Molecules



Biotherapeutics

Pipeline Snapshot*



Pipeline Focused on Compounds in High-Priority Diseases

* Pipeline snapshot as of Sept. 2010. Represents progress of R&D programs since 01/27/10; included are 92 NMEs plus 26 additional indications

Today's Late Stage Pfizer Portfolio

In Registration	
Celebrex *Chronic Pain*	**Lyrica** *GAD (monotherapy)*
Xiapex *Dupuytren's Contracture (MAA)*	**Pristiq** *Vasomotor Symptoms of Menopause*
Viviant *Osteoporosis Treatment and Prevention*	**Tafamidis meglumine** *transthyretin amyloidosis polyneuropathy (MAA)*
Apixaban *VTE prevention (MAA)*	**Taliglucerase alfa** *Gaucher Disease*
Macugen *Diabetic Macular Edema (MAA)*	**Prevenar 13 Adult** *Pneumococcal Disease*
Sutent *Pancreatic Neuroendocrine Tumors*	
Phase 3 (New Molecular Entities & Product Line Extensions)	
Apixaban *Venous Thromboembolism Treatment , Atrial Fibrillation*	**Aprela (bazedoxefine/conjugated estrogens)** *Menopausal Vasomotor Symptoms*
Axitinib *Renal Cell Carcinoma*	**Bapineuzumab** *Alzheimer's Disease*
Bosutinib *Chronic Myelogenous Leukemia*	**Neratinib** *Breast Cancer*
CP-690,550 (tasocitinib) *Rheumatoid Arthritis, Psoriasis*	**Lyrica** *Post Operative Pain, Epilepsy Monotherapy, Central Neuropathic Pain due to Spinal Chord Injury, Peripheral Neuropathic Pain*
Dimebon (latrepirdine) Alzheimer's, *Huntington's Disease*	**Crizotinib** *Non-Small Cell Lung Cancer*
Torisel *Renal Cell Carcinoma*	**Zithromax/Chloroquine** *Malaria*
Moxidectin *River Blindness*	**Tanezumab** *OA Signs and Symptoms (On Clinical Hold)*
PF-299804 *Lung Cancer*	**Eraxis/Vfend** *Aspergillosis*
Sutent *Adjuvant Renal Cell Carcinoma*	**Xiapex** *Peyronie's Disease*

Pfizer is a leader in Specialty Care with a Strong Presence in Oncology

Broad In-line Portfolio



Select Late-Stage Candidates in Specialty Care & Oncology

❖ Prevnar 13 for Adults (Vaccine)	Pneumococcal Disease
❖ Tasocitinib (JAK inhibitor)	Rheumatoid Arthritis
❖ Crizotinib (ALK inhibition)	Non-Small Cell Lung Cancer
❖ Axitinib (VEGF inhibition)	Metastatic Renal Cell Cancer

Prevnar 13 Adult:
An Important Healthcare Opportunity

High Incidence

- IPD incidence in adults >50 is similar to the incidence in children <5[1]
- Pneumococcal pneumonia >500,000 cases and 20,000 deaths/year in the US[1]

Significant Unmet Need

- IPD and Pneumococcal Pneumonia are associated with mortality and significant morbidity
- Existing polysaccharide vaccine has perceived limitations

Excellent Profile

- Building on the scientific foundation of Prevnar
- Potential to become the standard of care for the long-term prevention of pneumococcal disease in adults >50

Potential to Significantly Expand the Prevnar Franchise by Offering Effective and Long-Term PD Prevention to Adults

1. Weycker et al. (2010) Vaccine 28: 4955-4960.

Prevenar 13 Adult



- Placebo-controlled efficacy trial of vaccine-type community acquired pneumonia in adults >65 years
- Conducted in the Netherlands
- 84,000+ subjects enrolled, largest study of its kind

Tasocitinib (CP-690,550) is being Studied in a Wide Range of RA Patient Populations in the ORAL Trials Program

ORAL TRIALS
Advancing Clinical Research for RA

- **The Phase 3 program consists of six studies at more than 350 locations in 35 countries worldwide evaluating patients with active RA**
  - **More than 5000 people have taken tasocitinib in clinical trials, to date**

Trial Name	Description	Length	Status
ORAL Scan (1044)	Inadequate responders to methotrexate receive CP-690,550 and background methotrexate with a structural endpoint in addition to evaluating signs and symptoms and physical function	24 months	Ongoing
ORAL Solo (1045)	Inadequate responders to a DMARD (traditional or biologic) receive CP-690,550 monotherapy evaluating signs and symptoms and physical function	6 months	Complete; positive data presented at ACR 2010
ORAL Sync (1046)	Inadequate responders to a DMARD (traditional or biologic) receive CP-690,550 and background traditional DMARD	12 months	Ongoing
ORAL Standard (1064)	Inadequate responders to methotrexate receive CP-690,550 and background methotrexate, or active comparator of adalimumab and background methotrexate	12 months	Ongoing
ORAL Step (1032)	Inadequate responders to ≥ 1 TNF inhibitor receive CP-690,550 and background methotrexate	6 months	Ongoing
ORAL Start (1069)	Methotrexate-naïve patients receive CP-690,550 monotherapy with a structural endpoint also included in addition to evaluating signs and symptoms and physical function; this study has a methotrexate control arm	24 months	Ongoing

Tasocitinib (CP-690,550): A Novel, Oral Rheumatoid Arthritis Agent

CP-690,550 (Inflammation)

- Novel MOA inhibiting the Janus Kinase (JAK) inflammation pathway
- Large unmet medical need across multiple indications
- Potential to offer robust efficacy in an oral (tablet) form

Pfizer arthritis drug succeeds in late stage trial

- Meets goal on two of three primary endpoints -

- Significantly improves symptoms, physical function -

- Serious adverse events seen in 4.1 pct of patients -

NEW YORK, Nov 7 (Reuters) - A closely watched experimental drug for rheumatoid arthritis being developed by Pfizer Inc significantly reduced symptoms and improved physical function, according to data from a late-stage clinical trial. The drug, tasocitinib, met two of three primary goals of the 611-patient Phase III study at two tested doses, compared with a placebo, the data show. On the third primary goal, tasocitinib demonstrated a numerically higher measure of disease remission at three months than placebo, but that measure did not reach statistical significance.

Source: Reuters, Nov. 7

CP-690,550 is Being Evaluated in a Number of Other Inflammatory and Immunologic Diseases

	Phase of Development	Disease Prevalence* (2011)	Current Market* (2011)	Projected Market *(2019) (CAGR; 2011-2019)
Rheumatoid Arthritis	III	5.3M	$9.0B	$12.5B (4%)
Psoriasis	III	14.3M	$3.3B	$4.8B (5%)
Psoriatic Arthritis	II	1.3M	$1.6B	$2.0B (3%)
Ankylosing Spondylitis	II	1.2M	$1.4B	$1.8B (3%)
Crohn's Disease	II	1.0M	$3.4B	$4.2B (3%)
Ulcerative Colitis	II	1.4M	$1.6B	$2.3B (5%)

*Source: Decision Resources Institute

Pfizer has one of the strongest Phase III Oncology Pipelines in the Industry with a range of approaches to treating cancer



Oncology Focus on Personalized Medicine

Benefit to Clinical Development



Bigger Treatment Effect

Benefit to Patients



Patients Treated More Likely to Benefit

Longer Time on Treatment

Benefits of Approach

- Leverage patient selection strategies to reduce study size:
  - Less expensive
  - Faster completion
- Achieve earlier regulatory submission and launches
- Demonstrate dramatic treatment effect to facilitate early regulatory approval
- Demonstrate more robust value proposition to facilitate access

Crizotinib: Potential Breakthrough in Personalized Medicine For Lung Cancer Patients



Crizotinib's *Rapid Timeline from Research to Development*



Axitinib: Strong Efficacy Data Shows Potential for Differentiation – Key Asset in 1st in Class RCC Franchise



Sources: Decision Resources projected market growth rates (2007-2011; 13.9% and 2012-2019: 5.4%) applied 2009A RCC market sales ($1.2B). 2019 Sales by Class provided by Decision Resources (2008)

Pfizer Announces Positive Phase 3 Trial Results For Axitinib In Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)

NEW YORK, N.Y., Nov 19 – Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a generally manageable safety profile in this study.

Source: Pfizer Press Release, Nov. 19th

Pfizer's Structure Enhances Our Focus and Expertise Running Our Diverse Businesses

New Tools & Processes for Enhanced Decision-Making and Accountability for Development of Meaningful Medicines

Rich Pipeline with Several Assets in Registration and Late Stage Development

Delivering Scientific Advances That Impact Patients' Lives

Geno Germano

President / General Manager

Specialty Care & Oncology Business Units

J.P. Morgan Healthcare Conference

January 11, 2011

ADVANCING SCIENCE IMPROVING LIVES